Mohamed Wa'el Ahmed Hashad - Jun 28, 2024 Form 4 Insider Report for Akari Therapeutics Plc (AKTX)

Role
Director
Signature
/s/ Wendy F. DiCicco, as Attorney-in-Fact for Mohamed Wa'el Hashad
Stock symbol
AKTX
Transactions as of
Jun 28, 2024
Transactions value $
$0
Form type
4
Date filed
7/2/2024, 04:30 PM
Previous filing
Apr 12, 2024
Next filing
Aug 19, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKTX Stock Option (Right to Buy) Award $0 +5M $0.00 5M Jun 28, 2024 Ordinary Shares, par value $0.0001 per share 5M $0.00 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock options have an exercise price of $0.001395 per ordinary share, par value $0.0001 per share ("Ordinary Share").
F2 Non-qualified stock option granted under the Issuer's 2023 Equity Incentive Plan. One-hundred percent (100%) of the stock option vests and becomes exercisable on the date of the Issuer's 2025 Annual General Meeting of Shareholders, subject to continued service with the Issuer.
F3 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares.

Remarks:

See Exhibit 24.1 - Power of Attorney